Revenue
200 thousand USD
2015 · USD
Exact inputs and evidence
- Revenue: 200000 USD Source
Fundies. English
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
EDGAR101 filing records in this dataset, filed from 2005-11-09 to 2026-08-14. Reported financial figures are available; chart coverage varies by period.
Latest fiscal year
- Cash and cash equivalents
- 3.41 million USD Source
Exact value
3414263 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 15.4 million shares Source
Exact value
15417444 shares
Reported share-count change
459.21% · 12.7 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Net income
-6.08 million USD
2025-01-01 – 2025-12-31
Exact inputs and evidence
Operating cash flow
-5.46 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -1982720 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -1055968 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -3070618 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -1982720 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -1831363 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -3443224 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -1831363 USD · 2026-01-01 – 2026-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-14.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 1 of 11 periods available· newest 2015-12-31
- Operating income: 11 of 11 periods available· newest 2025-12-31
- Net income: 11 of 11 periods available· newest 2025-12-31
- Operating cash flow: 11 of 11 periods available· newest 2025-12-31
- capital expenditure: No compatible figures in this window
- Total assets: 11 of 11 periods available· newest 2025-12-31
- Total liabilities: 3 of 11 periods available· newest 2025-12-31
- Current assets: 11 of 11 periods available· newest 2025-12-31
- Current liabilities: 11 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 9 of 11 periods available· newest 2023-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 11 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 2.49 millionPrior period
−USD 3.59 million
–
Current period
−USD 6.08 million
–
Exact inputs and evidence
-6078593 − -3585965 = -2492628 USD
-3585965 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-6078593 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 93,918Prior period
−USD 3.16 million
–
Current period
−USD 3.07 million
–
Exact inputs and evidence
-3070618 − -3164536 = 93918 USD
-3164536 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-3070618 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 200K 2015
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2015 | Revenue | 200000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2015 | Year over year | No prior comparable period |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -1,323.2% 2015
Net margin -1,426.1% 2015
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2015 | Operating margin | -1,323.2% |
|
| 2015 | Net margin | -1,426.1% |
|
| 2015 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2015 | Operating cash flow | Not reported | No source recorded |
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2015 | Free cash flow | Unavailable | No source recorded |
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2015-12-31 | Liabilities / assets | Not reported |
|
Current assets to current liabilities
Current assets divided by current liabilities.
2.09× 2015
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2015 | Current assets / current liabilities | 2.09× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2016 2016-01-01 – 2016-12-31 | −USD 2.13 million Exact valueExact value: -2134732 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.68 million Exact valueExact value: -1677447 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2017 2017-01-01 – 2017-12-31 | −USD 1.81 million Exact valueExact value: -1808414 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.41 million Exact valueExact value: -1412181 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2018 2018-01-01 – 2018-12-31 | −USD 2.13 million Exact valueExact value: -2133128 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.51 million Exact valueExact value: -1511034 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2019 2019-01-01 – 2019-12-31 | −USD 2.44 million Exact valueExact value: -2440343 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1.67 million Exact valueExact value: 1674148 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2020 2020-01-01 – 2020-12-31 | −USD 3.26 million Exact valueExact value: -3264882 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.13 million Exact valueExact value: -2131414 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2021 2021-01-01 – 2021-12-31 | −USD 6.73 million Exact valueExact value: -6728396 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 4.14 million Exact valueExact value: -4142915 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2022-01-01 – 2022-12-31 | −USD 6.31 million Exact valueExact value: -6312535 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 4.61 million Exact valueExact value: -4611737 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | −USD 5.09 million Exact valueExact value: -5087029 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 4.29 million Exact valueExact value: -4293265 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 3.59 million Exact valueExact value: -3585965 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 3.16 million Exact valueExact value: -3164536 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −USD 6.08 million Exact valueExact value: -6078593 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 3.07 million Exact valueExact value: -3070618 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
101 filings · 2,530 latest values · 2,530 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001335105, 1335105, LIXT, NMAD, edgar:1335105, lixt
Also known as LIXTE BIOTECHNOLOGY HOLDINGS, INC., LIXTE BIOTECHNOLOGY HOLDINGS, INC., Lixte Biotechnology Holdings, Inc., NOMAD POWER SOLUTIONS, INC., SRKP 7 INC